PPARA and Hepatic steatosis: Furthermore, it is plausible that combination therapies, targeting different aspects of the disease (e.g., probiotics together with a PPAR agonist), are necessary to both target the initial disease driver and relieve the existing hepatic steatosis and inflammation.